Literature DB >> 29730378

Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.

Tomoki Tamura1, Etsuko Akimoto2, Chiaki Matsumoto3, Syunta Mori3, Tatuya Nishi3, Kennichiro Kudo3, Syouichi Kuyama3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29730378     DOI: 10.1016/j.jtho.2018.04.026

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  Vogt-Koyanagi-Harada disease during chemoimmunotherapy for non-small cell lung cancer.

Authors:  Yuri Kurono; Takayuki Takeda; Yusuke Kunimatsu; Nozomi Tani; Izumi Hashimoto; Kazuki Hirose
Journal:  Respirol Case Rep       Date:  2020-02-28

2.  Ocular Inflammation Induced by Immune Checkpoint Inhibitors.

Authors:  Florence Chaudot; Pascal Sève; Antoine Rousseau; Alexandre Thibault Jacques Maria; Pierre Fournie; Pierre Lozach; Jeremy Keraen; Marion Servant; Romain Muller; Baptiste Gramont; Sara Touhami; Habeeb Mahmoud; Pierre-Antoine Quintart; Stéphane Dalle; Olivier Lambotte; Laurent Kodjikian; Yvan Jamilloux
Journal:  J Clin Med       Date:  2022-08-25       Impact factor: 4.964

3.  Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy.

Authors:  Xiaowei Liu; Zheng Wang; Chan Zhao; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Li Zhang; Yue Li; Mengzhao Wang; Meifen Zhang; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-04       Impact factor: 3.500

Review 4.  [Clinical Diagnosis and Treatment Recommendations for Ocular Toxicities of Target Therapy and Immune Checkpoint Inhibitor Therapy].

Authors:  Xiaowei Liu; Zheng Wang; Chan Zhao; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Li Zhang; Yue Li; Mengzhao Wang; Juhong Shi; Meifen Zhang; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20

Review 5.  Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.

Authors:  Lin Zhou; Xin Wei
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.